Cytokine Release Syndrome and Sepsis Analogous Clinical Syndromes with Distinct Causes and Challenges in Management

被引:8
|
作者
Athale, Janhavi [1 ]
Busch, Lindsay M. [2 ]
O'Grady, Naomi P. [3 ]
机构
[1] Mayo Clin Arizona, Div Hematol & Oncol, Dept Crit Care Med, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
[2] Emory Univ Hosp, Dept Med, 550 Peachtree St Northeast, Atlanta, GA 30308 USA
[3] NIH, Internal Med Serv, Room 2-2734, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Cytokine release syndtome; Sepsis; Inflammatory clinical syndromes; COVID-19; Tocilizumab; CRITICALLY-ILL PATIENTS; T-CELL THERAPY; INFLAMMATORY SYNDROME; INFECTIONS; COVID-19; CYTOMEGALOVIRUS; TRANSPLANTATION; IMMUNOTHERAPY; TOCILIZUMAB; TOXICITIES;
D O I
10.1016/j.idc.2022.07.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review provides a broad framework for understanding CRS and other closely related syndromes. We have discussed several triggers of CRS, along with clinical syndromes that share significant overlap with both CRS and sepsis. Fig. 1 details CRS-associated conditions and shows the overlap between CRS and sepsis, along with the interplay of HLH and the COVID-19 pandemic. Given that both CRS and sepsis are clinical syndromes rather than distinct diseases, identifying and classifying patients at the bedside as having one or the other, or both, will remain challenging. The backbone for treatment of both CRS and sepsis remains excellent supportive care to maintain oxygenation and end-organ perfusion, with a focus on making the distinction quickly such that targeted therapies can be used.
引用
收藏
页码:735 / 748
页数:14
相关论文
共 50 条
  • [21] Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
    Schuster, Stephen J.
    Maziarz, Richard T.
    Rusch, Elisha S.
    Li, Junlong
    Signorovitch, James E.
    Romanov, Vadim V.
    Locke, Frederick L.
    Maloney, David G.
    BLOOD ADVANCES, 2020, 4 (07) : 1432 - 1439
  • [22] Management of cytokine release syndrome related to CAR-T cell therapy
    Hongli Chen
    Fangxia Wang
    Pengyu Zhang
    Yilin Zhang
    Yinxia Chen
    Xiaohu Fan
    Xingmei Cao
    Jie Liu
    Yun Yang
    Baiyan Wang
    Bo Lei
    Liufang Gu
    Ju Bai
    Lili Wei
    Ruili Zhang
    Qiuchuan Zhuang
    Wanggang Zhang
    Wanhong Zhao
    Aili He
    Frontiers of Medicine, 2019, 13 : 610 - 617
  • [23] Correlation of cytokine levels with clinical markers of organ hypoperfusion in sepsis syndrome patients (INTERSEPT trial)
    G Lemm
    J Carlet
    J Cohen
    Critical Care, 1 (Suppl 1):
  • [24] Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing entercolitis, or sepsis syndrome: Correlation with clinical parameters of inflammation and mortality
    Harris, MC
    D'Angio, CT
    Gallagher, PR
    Kaufman, D
    Evans, J
    Kilpatrick, L
    JOURNAL OF PEDIATRICS, 2005, 147 (04): : 462 - 468
  • [25] CAR-T-Recognition and treatment management of neurologic toxicities and cytokine release syndrome
    Nevo, Naama
    Khatib, Nimer
    Torati, Sigal
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 346 - 347
  • [26] Real world experience of teclistamab using a prompt management strategy for cytokine release syndrome
    Catamero, Donna
    Dai, Victoria
    Rattu, Mohammad
    Jagannath, Sundar
    Rodriguez, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S309 - S310
  • [27] Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
    Daoudlarian, D.
    Segot, A.
    Latifyan, S.
    Bartolini, R.
    Joo, V.
    Mederos, N.
    Bouchaab, H.
    Demicheli, R.
    Abdelhamid, K.
    Ferahta, N.
    Doms, J.
    Stalder, G.
    Noto, A.
    Mencarelli, L.
    Mosimann, V.
    Berthold, D.
    Stravodimou, A.
    Sartori, C.
    Shabafrouz, K.
    Thompson, J. A.
    Wang, Y.
    Peters, S.
    Pantaleo, G.
    Obeid, M.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 444 - 459
  • [28] Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences
    Tvedt, Tor Henrik Anderson
    Vo, Anh Khoi
    Bruserud, Oystein
    Reikvam, Hakon
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [29] DISTINCT CYTOKINE/CHEMOKINE PROFILE IN SJOGREN'S SYNDROME IS ASSOCIATED WITH DISEASE ACTIVITY AND CLINICAL MANIFESTIONS
    Perricone, C.
    Bursi, R.
    Cafaro, G.
    Ilenia, R.
    Calvacchi, S.
    Marcucci, E.
    Cipriani, S.
    Bistoni, O.
    Gerli, R.
    Bocci, E. Bartoloni
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 681 - 682
  • [30] Mind the gap: challenges in the clinical management of Lynch syndrome families
    Carin R Huizenga
    Arelis E Martir-Negron
    Kathleen R Blazer
    Julie O Culver
    Deborah J MacDonald
    Jeffrey N Weitzel
    Hereditary Cancer in Clinical Practice, 9 (Suppl 1)